19:34:24 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande


ListaMid Cap Stockholm
Elos Medtech är verksamma inom medicinteknik. Bolaget arbetar med forskning och utveckling av produkter och medicintekniska komponenter för dentala- och ortopediska implantat. Verksamheten bedrivs via egna anläggningar runtom Norden, Nordamerika och Asien. Kunderna utgörs huvudsakligen av internationellt verksamma företagskunder. Huvudkontoret ligger i Göteborg.


2024-02-22 Bokslutskommuniké 2023
2023-10-19 Kvartalsrapport 2023-Q3
2023-07-14 Kvartalsrapport 2023-Q2
2023-05-03 Årsstämma 2023
2023-04-26 Kvartalsrapport 2023-Q1
2023-02-23 Bokslutskommuniké 2022
2022-10-21 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-04 Ordinarie utdelning ELOS B 0.00 SEK
2022-05-03 Årsstämma 2022
2022-04-26 Kvartalsrapport 2022-Q1
2022-02-24 Bokslutskommuniké 2021
2021-12-22 Extra Bolagsstämma 2021
2021-10-20 Kvartalsrapport 2021-Q3
2021-07-16 Kvartalsrapport 2021-Q2
2021-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2021-05-03 Årsstämma 2021
2021-04-28 Kvartalsrapport 2021-Q1
2021-02-24 Bokslutskommuniké 2020
2020-10-20 Kvartalsrapport 2020-Q3
2020-07-16 Kvartalsrapport 2020-Q2
2020-05-05 Kvartalsrapport 2020-Q1
2020-04-22 Ordinarie utdelning ELOS B 0.00 SEK
2020-04-21 Årsstämma 2020
2020-02-18 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-18 Kvartalsrapport 2019-Q2
2019-04-24 Ordinarie utdelning ELOS B 1.00 SEK
2019-04-23 Kvartalsrapport 2019-Q1
2019-04-23 Årsstämma 2019
2019-02-18 Bokslutskommuniké 2018
2018-10-25 Kvartalsrapport 2018-Q3
2018-07-19 Kvartalsrapport 2018-Q2
2018-04-25 Ordinarie utdelning ELOS B 0.00 SEK
2018-04-24 Kvartalsrapport 2018-Q1
2018-04-24 Årsstämma 2018
2018-02-19 Bokslutskommuniké 2017
2017-10-24 Kvartalsrapport 2017-Q3
2017-08-25 Kvartalsrapport 2017-Q2
2017-04-27 Ordinarie utdelning ELOS B 1.30 SEK
2017-04-26 Årsstämma 2017
2017-04-26 Kvartalsrapport 2017-Q1
2017-02-24 Bokslutskommuniké 2016
2016-10-26 Kvartalsrapport 2016-Q3
2016-08-24 Kvartalsrapport 2016-Q2
2016-04-27 Ordinarie utdelning ELOS B 1.00 SEK
2016-04-26 Kvartalsrapport 2016-Q1
2016-04-26 Årsstämma 2016
2016-02-25 Bokslutskommuniké 2015
2015-10-23 Kvartalsrapport 2015-Q3
2015-08-21 Kvartalsrapport 2015-Q2
2015-04-28 Ordinarie utdelning ELOS B 2.00 SEK
2015-04-28 Bonusutdelning ELOS B 1
2015-04-27 Kvartalsrapport 2015-Q1
2015-04-27 Årsstämma 2015
2015-02-19 Bokslutskommuniké 2014
2014-10-24 Kvartalsrapport 2014-Q3
2014-08-22 Kvartalsrapport 2014-Q2
2014-04-30 Ordinarie utdelning ELOS B 2.00 SEK
2014-04-29 Kvartalsrapport 2014-Q1
2014-04-29 Årsstämma 2014
2014-02-21 Bokslutskommuniké 2013
2013-10-23 Kvartalsrapport 2013-Q3
2013-08-21 Kvartalsrapport 2013-Q2
2013-04-26 Ordinarie utdelning ELOS B 1.00 SEK
2013-04-25 Årsstämma 2013
2013-04-25 Kvartalsrapport 2013-Q1
2013-02-22 Bokslutskommuniké 2012
2012-10-26 Kvartalsrapport 2012-Q3
2012-08-22 Kvartalsrapport 2012-Q2
2012-04-24 Ordinarie utdelning ELOS B 1.50 SEK
2012-04-23 Årsstämma 2012
2012-04-23 Kvartalsrapport 2012-Q1
2012-02-24 Bokslutskommuniké 2011
2011-10-26 Kvartalsrapport 2011-Q3
2011-08-18 Kvartalsrapport 2011-Q2
2011-05-04 Ordinarie utdelning ELOS B 1.50 SEK
2011-05-03 Årsstämma 2011
2011-05-03 Kvartalsrapport 2011-Q1
2011-02-25 Bokslutskommuniké 2010
2010-10-27 Kvartalsrapport 2010-Q3
2010-08-19 Kvartalsrapport 2010-Q2
2010-04-29 Ordinarie utdelning ELOS B 0.00 SEK
2010-04-28 Kvartalsrapport 2010-Q1
2010-02-25 Bokslutskommuniké 2009
2009-10-23 Kvartalsrapport 2009-Q3
2009-08-20 Kvartalsrapport 2009-Q2
2009-04-30 Ordinarie utdelning ELOS B 1.50 SEK
2009-04-29 Årsstämma 1
2009-04-29 Kvartalsrapport 2009-Q1
2008-04-29 Ordinarie utdelning ELOS B 1.50 SEK
2007-04-26 Ordinarie utdelning ELOS B 0.50 SEK
2006-04-28 Ordinarie utdelning ELOS B 1.25 SEK
2005-05-20 Split ELOS B 1:2
2005-05-04 Ordinarie utdelning ELOS B 2.50 SEK
2004-04-30 Ordinarie utdelning ELOS B 0.00 SEK
2003-05-07 Ordinarie utdelning ELOS B 0.00 SEK
2002-04-26 Ordinarie utdelning ELOS B 0.00 SEK
2001-04-27 Ordinarie utdelning ELOS B 2.25 SEK
1995-06-15 Split ELOS B 1:2
2021-07-16 08:00:00


April - June 2021
  • Net sales for the second quarter amounted to SEK 181.0 (118.3) million, an increase of 53 percent compared with the same period last year. Net sales in local currencies increased by 63 percent.
  • Operating profit amounted to SEK 26.5 (14.9) million, corresponding to an operating margin of 14.7 (12.6) percent. In the second quarter of last year government grant and subsidies due to Covid-19 had a positive impact of SEK 38.9 million on operating profit.
  • Earnings after net financial items amounted to SEK 22.8 (9.1) million. Exchange rate differences and revaluation of interest rate swaps had a negative impact on net financial items of SEK -0.9 (-2.6) million and SEK -0.4 (-0.1) million, respectively, resulting in a net financial loss of SEK -3.7 (-5.8) million.
  • Earnings after tax amounted to SEK 18.4 (6.9) million.
  • Cash flow from operating activities was SEK 34.3 (50.2) million, amounting to SEK 24.0 (34.2) million after investments.
  • Earnings per share amounted to SEK 2.28 (0.87).


Elos Medtech has maintained the positive trend from the beginning of the year, reporting growth of 6 percent compared with the first quarter and 53 percent compared with the coronavirus-hit second quarter of 2020. The gross margin also remained stable during the quarter.

Dental grew by 12 percent compared with the previous quarter. We have a good position, with an established product range. During the quarter we also launched additional products in the Elos Accurate® family that were well received by the market. This gives dental implant professionals a wider range of options and thus expands the area of use for our hybrid base.

Orthopedics had a strong second quarter. Thanks to our product mix as well as efficiencies and low staffing levels we have increased our margins in the business area. All machines at our Memphis site were validated in the spring and we are now well equipped to further expand production. However, due to the strong demand we are seeing for robotic-assisted surgery products our organization is currently undersized. We are therefore working hard to recruit staff to the site with the current challenge that workers with this skills profile are in strong demand in the US. This situation has resulted in strong short-term results but we expect recruitment to be a long-term challenge. 

In Life Science our profitability has remained stable and we proceed to make continuous improvements in production. In June our new production hall in Skara was classified as a cleanroom. The move has gone very well with no disruptions for our customers and we are now ready to start production in the third quarter.

Our focused efforts in Operational Excellence with margin improvement measures have produced clear results. A higher degree of automation has streamlined flows and improved quality, contributing to increased profitability. Growth has gone more or less hand in hand with profitability, although earnings were down slightly on the first quarter. In all business areas we have experienced certain problems with the delivery of raw materials as well as an increase in the prices of steel and plastics. This is something that we are actively monitoring and addressing, as it could have an impact on our earnings in the long run.

Our medical technology business gives us a stable foundation on which to stand, as we have a direct positive impact on people's lives. We are also aware that the ongoing pandemic could spring a surprise on the world market and therefore maintain preparedness for handling any setbacks.

On July 7 TA Associates announced that it controls 73.1 percent of the shares of Elos Medtech. I welcome TA Associates as the company's new majority owner and would like to take this opportunity to thank all our shareholders, many of whom have held their shares since the company's IPO in 1989. Over the past three decades, we have worked together as a listed company to streamline, acquire and build a strong global corporate group. The key to our success has been a strong local foothold with motivated, skilled and not least loyal employees. We have consistently had a clear strategy to develop our offering and grow more than the market, which we continue to work with.